What is the 411 on the New 988 Hotline?
The 988 Lifeline will connect callers with specialists trained to assist with mental health crises, including psychotic symptoms and substance...
Even after Lockdowns Eased, Pandemic Depression Persisted Across Social Classes
One year into the COVID-19 pandemic, we found that more than 1 in 5 U.S. adults reported probable depression in...
Vaccine Hesitancy is Complicating Physicians’ Obligation to Respect Patient Autonomy
Autonomy is one of the pillars of bioethics, and it is the notion that the patient has the ultimate decision-making...
The COVID-19 Pandemic Offers an Opportunity to Make a Healthy Shift in Body Ideals
The COVID-19 pandemic has changed everyday life for many people in both trivial and profound ways, including how they look...
What is the New COVID-19 Variant BA.2?
While the origin of BA.2 is still unclear, it has become the dominant strain in many countries, including India, Denmark...
Abortion Pills are Just as Safe to Prescribe Online as After an In-person Exam
When medication abortion, or abortion with pills, was introduced to the U.S. in 2000, it offered a more accessible option...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more